Medical Device
Manufacturing
THE TRADE PAPER OF THE FACTORY FLOOR
Z-1038-2017Class II

AFX Endovascular AAA System, Endoleak Type IIIB; The AFX Endovascular AAA System is intended for endovascular...

Endologix LLC / initiated 2016-12-27 / Terminated / root cause: labeling and UDI

Endologix began a recall of AFX Endovascular AAA System, Endoleak Type IIIB; The AFX Endovascular AAA System is intended for endovascular treatment of patients with abdominal aortic or... on . FDA classified it as Class II and gives the reason as "Endologix updated the Instructions for Use (IFU) and implemented modifications to the AFX Endovascular AAA System (AFX System)". As of , the recall status on record is Terminated, and MDM tags the root cause as labeling and UDI.

Recall record

Recall number
Z-1038-2017
Classification
Class II
Status
Terminated
Initiated
Posted
Terminated
Recalling firm
Endologix LLC
Product
AFX Endovascular AAA System, Endoleak Type IIIB; The AFX Endovascular AAA System is intended for endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms (AAA).
Product code
MIH System, Endovascular Graft, Aortic Aneurysm Treatment
Reason for recall
Endologix updated the Instructions for Use (IFU) and implemented modifications to the AFX Endovascular AAA System (AFX System).
Root cause tag
labeling and UDI
FDA root cause
Other
Action
A Dear Physician letter dated 6/2/15 was sent to customers to inform them that the 2014 Clinical Update on the Endologix Endovascular Systems for AAA Repair. The letter provides update reports for the cumulative clinical data and information on the Powerlink System and the AFX Endovascular AAA System (AFX System). On January 2016, a Dear Physician letter was sent to customers to inform them of the 2015 Clinical Update covering the Endologix Endovascular Systems for AAA Repair. The letter provided update reports on the cumulative clinical data and commercial experience (i.e., post-market surveillance) of the Powerlink System and the AFX Endovascular AAA system and contains important information and recommendations regarding the continued safe and effective use of these devices. A Dear Physician letter dated 12/27/16 will be sent to inform customers of the important information related to the AFX Endovascular AAA System (AFX System). The letter provides a series of updates to the Instructions for Use (IFU) and modifications to the product were implemented, including introduction of a graft material processing improvement known as Duraply. Customers with any questions are instructed to contact their Endologix representative.
Quantity in commerce
40967
Distribution
US and worldwide: Austria, Belgium, Czech Republic, France, Germany, Greece, Ireland, Israel, Italy, Latvia, Luxembourg, Monaco, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, Turkey, United Kingdom.
Product codes and lots
The correction is not lot specific. It applies to AFX procedures conducted after July 2015

Enforcement reports

One row per recalled product line
FDA enforcement reports joined to recall event Z-1038-2017
Recall numberClassStatusVoluntary or mandatedReport dateClassified
Z-1038-2017Class IITerminatedVoluntary: Firm initiated